Last updated: August 1, 2026
Migranal is the former brand name for dihydroergotamine mesylate nasal spray, a prescription acute migraine treatment. The FDA approved Migranal in 1997 for the acute treatment of migraine attacks with or without aura in adults.[1] The product’s clinical development is mature, its original patent estate has expired, and its commercial position has shifted from branded Migranal to generic dihydroergotamine nasal spray and newer device-enabled products such as Trudhesa.
Migranal has no meaningful active clinical-trial pipeline as a branded product. Its market is a legacy segment within acute migraine therapy, competing with triptans, gepants, ditans and newer dihydroergotamine delivery systems.
What is Migranal and how does dihydroergotamine work?
Migranal contains dihydroergotamine mesylate, an ergot alkaloid administered through a nasal spray. It is used for the acute treatment of migraine attacks and is not indicated for preventive migraine therapy.[1]
Dihydroergotamine acts primarily through serotonergic mechanisms, including agonist activity at several 5-HT receptor subtypes, with additional effects at adrenergic and dopaminergic receptors. The pharmacology produces cranial vasoconstriction and inhibition of trigeminal neurogenic inflammation.
The original Migranal product delivered a metered dose through a nasal spray device. The FDA label instructed patients to administer one spray into each nostril, with a second dose permitted after 15 minutes when needed. The labeled maximum was two doses in a 24-hour period and three doses in a seven-day period.[1]
Migranal product profile
| Attribute |
Migranal |
| Active ingredient |
Dihydroergotamine mesylate |
| Dosage form |
Nasal spray |
| Original indication |
Acute treatment of migraine with or without aura |
| Preventive use |
Not indicated |
| FDA approval |
1997 |
| Original application |
NDA 020918 |
| Sponsor history |
Novartis, later transferred commercial rights |
| Administration |
Intranasal |
| Therapeutic class |
Ergot migraine therapy |
| Current status |
Legacy/discontinued branded product with generic and successor-product competition |
What is the FDA and regulatory status of Migranal?
The original branded Migranal product is no longer the principal commercial product in the U.S. FDA records distinguish between a drug’s approval history and its commercial availability. A product can remain listed in regulatory databases even after the branded product is discontinued.
The FDA’s Orange Book identifies approved drug products and patent or exclusivity information. Migranal’s original regulatory exclusivity period ended long ago, and its core composition and use patents are no longer barriers to generic entry.[2]
Generic dihydroergotamine mesylate nasal spray products have been marketed in the U.S. under abbreviated new drug applications. Generic approval requires pharmaceutical equivalence and bioequivalence to the reference-listed drug, rather than a new efficacy program comparable to the original Migranal development program.
FDA regulatory milestones
| Year |
Regulatory event |
| 1997 |
FDA approval of Migranal nasal spray |
| 2000s |
Generic development and abbreviated-approval activity expanded |
| 2010s |
Branded Migranal commercial availability declined |
| 2019-2020 |
Generic and alternative DHE nasal products remained the principal competitive pathway |
| 2021 |
FDA approved Trudhesa, a new DHE nasal-delivery product using the POD device[3] |
What patents protect Migranal?
Migranal’s original patent protection has expired. The product does not have a commercially meaningful unexpired composition-of-matter patent that would prevent generic dihydroergotamine nasal spray competition.
The relevant patent categories were:
- Dihydroergotamine as an established active ingredient.
- Intranasal administration for acute migraine treatment.
- Nasal-spray formulation and delivery-device configurations.
- Method-of-use claims covering acute treatment of migraine.
Because dihydroergotamine predates modern pharmaceutical patent practice, the active ingredient itself is not protected by a current U.S. composition-of-matter patent. Any remaining rights associated with later delivery systems would attach to those specific products rather than to Migranal’s basic active ingredient.
Migranal patent-estate assessment
| Patent category |
Current barrier to generic Migranal |
Assessment |
| Active ingredient |
None |
Expired |
| Basic migraine indication |
None |
Expired or not commercially blocking |
| Original nasal formulation |
None of material commercial duration |
Expired |
| Original metered-dose device |
None for legacy Migranal |
Expired or obsolete |
| Later DHE delivery technology |
Product-specific |
Relevant to successor products, not Migranal |
| Manufacturing know-how |
Potentially relevant |
Does not replace an expired product patent |
The practical patent risk is therefore low for a conventional generic equivalent. The more important intellectual-property question concerns newer delivery systems, particularly devices designed to improve nasal absorption or reduce variability in patients with migraine-related nausea and gastric stasis.
When did Migranal lose exclusivity?
Migranal lost meaningful market exclusivity after the expiration of its original FDA exclusivity and patent protections. The exact commercial transition occurred over several years as generic manufacturers entered and branded sales declined.
FDA exclusivity and patent expiration are separate events:
- FDA exclusivity delayed approval of certain competing applications for a defined statutory period.
- Patent protection could delay generic launch beyond the exclusivity period.
- Once both barriers ended, generic manufacturers could enter through ANDA pathways.
- Device-specific later patents did not restore exclusivity to the original Migranal brand.
Migranal therefore has no present-day exclusivity comparable to a recently approved migraine therapy. Its remaining commercial value depends on manufacturing economics, pharmacy access, formulary placement and prescriber familiarity.
Are there active clinical trials for Migranal?
There is no major active clinical-development program for Migranal as a branded drug. The product’s efficacy and safety were established before current migraine-trial standards became common, and development activity has moved toward improved delivery systems and newer mechanisms.
Clinical research involving dihydroergotamine has focused on:
- Alternative nasal delivery technologies.
- Inhaled or orally inhaled dihydroergotamine.
- Injectable delivery.
- Pharmacokinetic optimization.
- Acute-migraine rescue treatment.
- Comparative tolerability and convenience.
- Device performance in patients with nausea or impaired gastric emptying.
The most commercially relevant modern development was Trudhesa, approved by the FDA in 2021 for the acute treatment of migraine with or without aura in adults.[3] Trudhesa uses Precision Olfactory Delivery, a device intended to deliver medication to the upper nasal space. Its development was directed at limitations associated with conventional nasal sprays, including inconsistent absorption.
Clinical-development comparison
| Product |
Active ingredient |
Delivery system |
Development status |
| Migranal |
Dihydroergotamine mesylate |
Conventional nasal spray |
Legacy product |
| Generic DHE nasal spray |
Dihydroergotamine mesylate |
Conventional nasal spray |
Generic commercial pathway |
| Trudhesa |
Dihydroergotamine mesylate |
POD nasal delivery |
FDA-approved successor technology |
| D.H.E. 45 |
Dihydroergotamine mesylate |
Intravenous or intramuscular injection |
Established injectable product |
| New migraine agents |
CGRP antagonists or 5-HT1F agonists |
Oral, injectable or nasal |
Active commercial and clinical competition |
What is the competitive landscape for Migranal?
Migranal competes in a crowded acute-migraine market. Its principal competitive groups are triptans, gepants, ditans and other dihydroergotamine products.
Triptans
Sumatriptan, rizatriptan, eletriptan, zolmitriptan, naratriptan, almotriptan and frovatriptan are established acute-migraine therapies. Most are available as generics. They generally have greater physician familiarity and broader formulary access than dihydroergotamine.
Triptans remain subject to cardiovascular contraindications and precautions. Dihydroergotamine has similar vasoconstrictive restrictions and can be less attractive where cardiovascular risk limits use.
Gepants
Ubrogepant, rimegepant and zavegepant compete with DHE products without the same vasoconstrictive pharmacology. Gepants have gained share because they address patients who do not respond adequately to triptans or cannot use them because of contraindications.
Zavegepant is a nasal CGRP receptor antagonist and competes directly with intranasal DHE products on route of administration. Its value proposition includes non-vasoconstrictive pharmacology and use in patients seeking an alternative to oral treatment.[4]
Ditans
Lasmiditan is a 5-HT1F agonist approved for acute migraine. It does not have the vasoconstrictor profile of triptans or DHE, but driving restrictions and central nervous system adverse effects affect its positioning.[5]
Competitive positioning
| Treatment |
Key advantage over Migranal |
Key limitation |
| Generic triptans |
Low cost and broad familiarity |
Cardiovascular restrictions; variable response |
| Gepants |
Non-vasoconstrictive mechanism |
Higher cost; payer controls |
| Zavegepant |
Non-oral nasal option |
Newer product with access and pricing barriers |
| Trudhesa |
Improved DHE nasal-delivery technology |
DHE class restrictions and device complexity |
| Injectable DHE |
Reliable systemic delivery |
Injection burden and clinical-use limitations |
| Migranal/generic DHE spray |
Established nasal route; low development risk |
Older device, tolerability and absorption concerns |
What is the market size and revenue outlook for Migranal?
Migranal should not be analyzed as a high-growth branded franchise. The original brand has limited standalone revenue visibility, and available public company disclosures generally report migraine portfolios at broader product or business-unit levels rather than separating legacy Migranal sales.
The addressable market is the acute-migraine-treatment market, which includes branded and generic triptans, gepants, ditans, DHE products and over-the-counter analgesics. DHE nasal spray represents a small specialty segment within that market.
Market drivers
The main positive drivers are:
- Large diagnosed migraine population.
- Demand for non-oral delivery during nausea or vomiting.
- Use in patients with inadequate triptan response.
- Continued physician familiarity with DHE.
- Generic pricing that can support pharmacy access.
- Need for rescue therapy in difficult acute attacks.
The main negative drivers are:
- Generic competition.
- Low differentiation of conventional nasal spray.
- Vasoconstriction-related restrictions.
- Competition from CGRP antagonists.
- Limited promotional investment in a legacy product.
- Device and administration complexity.
- Reimbursement pressure.
Five-year commercial projection
A product-specific Migranal forecast is best modeled as a declining legacy franchise rather than a growth asset. The assumptions below reflect the product’s mature status, generic competition and substitution by newer migraine medicines.
| Scenario |
2025-2026 |
2027-2029 |
Commercial interpretation |
| Base case |
Stable to low-single-digit decline |
Mid-single-digit annual decline |
Generic DHE retains a small rescue-treatment niche |
| Upside case |
Low-single-digit growth |
Flat to low-single-digit growth |
Improved access, supply stability or renewed DHE use |
| Downside case |
Mid-single-digit decline |
High-single-digit decline |
Gepants and nasal CGRP products accelerate substitution |
The base case is more consistent with a mature generic market. Revenue growth is unlikely to come from Migranal itself. Any meaningful expansion would more likely arise from a differentiated delivery platform, a branded successor product or a broader DHE portfolio.
What generic entry risks exist for Migranal?
Generic launch risk is high because the original product lacks meaningful patent protection. Generic manufacturers do not need to overcome a current composition-of-matter patent, and the therapeutic ingredient has extensive historical clinical use.
The principal barriers are commercial rather than legal:
- Maintaining reliable DHE supply.
- Meeting nasal-spray manufacturing specifications.
- Demonstrating bioequivalence.
- Managing device reproducibility.
- Securing pharmacy and wholesaler distribution.
- Avoiding product shortages.
- Competing against low-cost generic triptans.
A conventional generic DHE nasal spray can enter without infringing successor-product patents if it uses a materially different device and does not practice protected claims directed to a newer delivery platform.
Which companies are challenging Migranal’s market position?
The strongest competitive pressure comes from companies commercializing newer migraine mechanisms rather than from patent litigation against Migranal.
| Company or product group |
Competitive threat |
| Generic manufacturers |
Price erosion and substitution |
| Impel Pharmaceuticals and Trudhesa |
Differentiated DHE nasal delivery |
| Pfizer and other triptan suppliers |
Broad generic and branded triptan access |
| AbbVie |
Ubrogepant and broader CGRP portfolio |
| Biohaven/Pfizer |
Rimegepant and preventive-plus-acute positioning |
| Zydus and other zavegepant suppliers |
Non-vasoconstrictive nasal acute therapy |
| Eli Lilly |
Lasmiditan and migraine portfolio competition |
The relevant competitive question is not whether a company is challenging Migranal through Paragraph IV litigation. It is whether prescribers and payers will choose non-DHE therapies for the same acute-migraine patients.
What is the Paragraph IV and litigation status of Migranal?
Migranal is not associated with a current, material Paragraph IV litigation campaign that would determine market entry. The original patent estate is too old to create the type of active patent dispute seen with recently launched migraine drugs.
Paragraph IV risk historically would have applied to an ANDA applicant alleging that listed patents were invalid, unenforceable or not infringed. For Migranal, the commercial relevance of that pathway has largely passed because the original patents have expired or no longer function as meaningful barriers.
Litigation risk remains more relevant to successor DHE products with device, formulation or method-of-use patents. Those disputes would concern the successor product’s proprietary delivery technology, not the basic Migranal active ingredient.
Are formulation and method-of-use patents still important?
Formulation and device patents are more important than active-ingredient patents in the DHE nasal market.
Formulation patents
Potential formulation claims can address:
- Dihydroergotamine concentration.
- Stabilizers and preservatives.
- pH range.
- Spray performance.
- Droplet size.
- Absorption-enhancing excipients.
- Container-closure systems.
- Dose uniformity.
These claims may protect a specific product but do not necessarily block all generic DHE nasal sprays.
Method-of-use patents
Potential method claims can address:
- Acute treatment of migraine.
- Administration at the onset of symptoms.
- Treatment in patients with nausea or vomiting.
- Use after failure of oral medication.
- Repeat-dose protocols.
- Delivery to the upper nasal cavity.
Method-of-use patents have narrower practical value when the underlying indication is established and physicians can prescribe generic DHE for the approved migraine indication. Their effect depends on claim scope, labeling and induced-infringement evidence.
How strong is the Migranal patent estate?
The Migranal patent estate is weak as a current commercial barrier.
| Criterion |
Rating |
Reason |
| Composition-of-matter protection |
Very weak |
Dihydroergotamine is an old active ingredient |
| Core indication protection |
Very weak |
Acute migraine use is established and old |
| Conventional nasal formulation |
Weak |
Generic substitution is available |
| Delivery-device protection |
Weak for Migranal; stronger for successor products |
Technology-specific rights may remain elsewhere |
| Regulatory exclusivity |
None material |
Approval occurred decades ago |
| Litigation leverage |
Low |
No current blocking estate of major significance |
| Manufacturing know-how |
Moderate |
Can affect supply and quality, not generic legality |
| Commercial durability |
Low to moderate |
Niche demand remains, but growth is limited |
What is the likely generic launch scenario?
The most likely scenario is continued availability of low-cost generic DHE nasal spray, with gradual volume erosion as gepants and other non-vasoconstrictive therapies expand.
A generic entrant would likely pursue one of three strategies:
- Compete on price through pharmacy and wholesaler channels.
- Target specialists and patients who prefer intranasal rescue treatment.
- Use manufacturing reliability and supply continuity as the main differentiator.
A branded relaunch of Migranal would face substantial hurdles. The brand would need a differentiated device, improved patient experience, payer coverage or evidence supporting use in a defined treatment-resistant population.
What manufacturing and intellectual-property barriers affect DHE nasal products?
The active ingredient is not the main manufacturing barrier. The difficult components are formulation consistency, device engineering and nasal delivery performance.
Manufacturers must control:
- Dose uniformity from the spray mechanism.
- Stability of the formulation.
- Container and actuator compatibility.
- Microbial quality.
- Nasal deposition.
- Product performance across storage conditions.
- Supply of pharmaceutical-grade dihydroergotamine mesylate.
These factors can produce regulatory and commercial barriers even when patent protection is limited. A generic product may be legally approvable but commercially unsuccessful if it has poor spray performance, intermittent supply or unfavorable reimbursement.
How does Migranal compare with Trudhesa?
Trudhesa is the closest branded successor in terms of active ingredient and route. Its differentiation is the POD delivery system, which was developed to improve deposition in the upper nasal space.[3]
| Attribute |
Migranal |
Trudhesa |
| Active ingredient |
Dihydroergotamine mesylate |
Dihydroergotamine mesylate |
| Nasal technology |
Conventional spray |
POD delivery system |
| Patent position |
Legacy and largely expired |
Product-specific technology may be protected |
| Market role |
Generic or discontinued legacy product |
Branded differentiated product |
| Main value proposition |
Familiar DHE nasal treatment |
Delivery optimization and convenience |
| Main risks |
Generic erosion and substitution |
Pricing, access, device adoption and DHE class restrictions |
Trudhesa does not revive Migranal’s expired patent estate. It creates a separate product opportunity based on delivery technology.
What is the investment outlook for Migranal?
Migranal is unlikely to support a conventional growth-equity thesis as a standalone asset. Its value is more consistent with:
- A low-cost generic portfolio addition.
- A specialty migraine rescue product.
- A platform opportunity involving improved DHE delivery.
- A licensing target with complementary nasal or device technology.
- A manufacturing and supply-chain asset.
Revenue exposure is likely to be modest unless attached to a broader migraine portfolio. The strongest commercial opportunity is not the legacy Migranal brand. It is differentiated delivery in patients who need rapid non-oral treatment and who have limited benefit from oral medicines.
Key Takeaways
- Migranal is the former branded nasal-spray formulation of dihydroergotamine mesylate.
- FDA approval occurred in 1997 for acute migraine treatment in adults.
- The original product’s patent and exclusivity barriers have expired.
- No major active clinical-trial program supports Migranal as a branded product.
- Generic DHE nasal spray faces low legal entry barriers but meaningful manufacturing and commercial barriers.
- Trudhesa is the closest modern branded successor, using a proprietary nasal-delivery approach.
- Gepants, zavegepant, triptans and lasmiditan pose greater long-term commercial pressure than patent litigation.
- Migranal is a mature, low-growth niche product rather than a platform with substantial standalone revenue potential.
- The strongest remaining IP value lies in formulation, device and delivery technology, not in dihydroergotamine itself.
Frequently Asked Questions
Is Migranal still available in the United States?
The branded Migranal product has largely left the U.S. commercial market, while generic dihydroergotamine mesylate nasal-spray products and newer DHE delivery products may remain available.
Is dihydroergotamine nasal spray a generic drug?
Yes. Generic dihydroergotamine mesylate nasal spray products can be approved through the FDA ANDA pathway when they demonstrate equivalence to the reference product.
Does Migranal have an unexpired U.S. patent?
Migranal’s original active-ingredient, indication and conventional nasal-spray patent protection is not a current material barrier to generic entry.
Is Trudhesa the same drug as Migranal?
Both contain dihydroergotamine mesylate, but Trudhesa uses a different nasal-delivery system and is positioned as a differentiated successor product.
Can Migranal be used for migraine prevention?
No. The FDA-approved indication is acute treatment of migraine attacks. It is not approved for preventive migraine therapy.[1]
References
-
U.S. Food and Drug Administration. (1997). Migranal (dihydroergotamine mesylate) nasal spray prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2021). Trudhesa (dihydroergotamine mesylate) nasal spray prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Zavzpret (zavegepant) nasal spray prescribing information. FDA.
-
U.S. Food and Drug Administration. (2019). Reyvow (lasmiditan) prescribing information. FDA.
